Zhong Guo Xin Wen Wang·2025-10-30 06:57Core Viewpoint - Fosun Pharma will showcase its innovative pharmaceutical products and high-end medical devices at the 8th China International Import Expo (CIIE), emphasizing its role as a global healthcare industry leader rooted in China [1][2]. Group 1: Company Achievements - Fosun Pharma has successfully transformed from an exhibitor to an investor, leveraging the CIIE to accelerate the localization of advanced technologies and innovative medical products in China [1]. - The company has introduced at least six innovative products, referred to as "CIIE babies," which have been successfully launched or approved in China, including the Da Vinci surgical robot and the CAR-T cell therapy product Yikaida® [2][3]. Group 2: Product Innovations - The Marie® vertical particle therapy system, a revolutionary breakthrough in tumor radiotherapy, has been highlighted for its compact design, reducing the required space from 120 square meters to 30 square meters, thus lowering construction and operational costs [2]. - Yikaida®, as China's first approved CAR-T product, has benefited over 1,000 lymphoma patients since its approval in 2021, showcasing the positive impact of the CIIE on global resource collaboration [3]. Group 3: Future Directions - Fosun Pharma aims to focus on industry upgrades and embrace innovative products in future CIIE participations, seeking to gather more global resources as a multinational enterprise [3].